More recently, the FDA granted accelerated approval to humanized mAb Hu3F8 (Naxitamab, DANYELZA®) in combination with GM-CSF for relapsed or refractory high-risk neuroblastoma in the bone or bone marrow, based on overall response rate and duration of response in two clinical trials (NCT03363373 and NCT01757626). Here, CSF2 is linked to neuroblastoma.